Pathophysiology and treatment of cardiac amyloidosis (Q38259728)

1 September 2017

1 reference

title

Pathophysiology and treatment of cardiac amyloidosis (English)

1 reference

1 September 2017

1 reference

2

1 reference

1 September 2017

1

Morie A Gertz

1 reference

1 September 2017

3

Taimur Sher

1 reference

PubMed ID

25311231

1 September 2017

language of work or name

English

0 references

publication date

14 October 2014

1 reference

Nature Reviews Cardiology

1 September 2017

1 reference

1 September 2017

12

1 reference

1 September 2017

91-102

1 reference

1 September 2017

2

1 reference

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

1 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Localized amyloidosis of the genitourinary tract: report of 5 new cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Tracheobronchial amyloidosis managed with multimodality therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Role of mutations in the cellular internalization of amyloidogenic light chains into cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Amyloid formation in light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Systemic amyloidosis in England: an epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Serum-free light-chain assay: clinical utility and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Type I primary neuropathic amyloidosis (Andrade, portuguese)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Transthyretin mutations in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Genotype, echocardiography, and survival in familial transthyretin amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Transthyretin valine-94-alanine, a novel variant associated with late-onset systemic amyloidosis with cardiac involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Senile systemic amyloidosis: clinical features at presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

An N-terminal pro-atrial natriuretic peptide (NT-proANP) 'aggregation-prone' segment involved in isolated atrial amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Prevalence of isolated atrial amyloidosis in young patients affected by congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Biochemical characterisation of amyloid by endomyocardial biopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Clinical proteomics for diagnosis and typing of systemic amyloidoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Pitfalls in the diagnosis of primary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Relationship between monoclonal gammopathy and cardiac amyloid type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Leukocyte chemotactic factor 2 amyloidosis cannot be reliably diagnosed by immunohistochemical staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

How to diagnose amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Cardiac amyloidosis: updates in diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

The prognostic significance of central hemodynamics in patients with cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Infiltrative cardiovascular diseases: cardiomyopathies that look alike

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Strain and strain rate imaging in cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Advanced cardiac amyloidosis associated with normal interventricular septal thickness: an uncommon presentation of infiltrative cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Imaging in systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Biological treatment in adult-onset Still's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Diffuse diseases of the myocardium: MRI-pathologic review of cardiomyopathies with dilatation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Long term survival in patients with cardiac amyloidosis. Prevalence and characterisation during follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

New insights and modern treatment of AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Cardiac amyloidosis: an approach to diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Implantable cardioverter defibrillators in patients with cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Out-of-hospital cardiac arrest in patients with cardiac amyloidosis: presenting rhythms, management and outcomes in four patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Left ventricular device implantation for advanced cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Primary systemic amyloidosis with ischemic stroke as a presenting complication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

How to manage primary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Amyloidosis: pathogenesis and new therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Cardiac changes in systemic amyloidosis: Visualisation by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Genotype – phenotype correlation in FAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

The changing face of AA amyloidosis: a single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Dynamic left ventricular outflow tract obstruction in senile cardiac amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Isolated atrial amyloidosis and the importance of molecular classification.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

The association of atrial tachyarrhythmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Complications of echocardiography-guided endomyocardial biopsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Immunohistochemical examination of Aκ amyloidosis with antibody against adjacent portion of the carboxy terminus of immunoglobulin kappa light chain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Deposition of amyloid proteins in the epicardial coronary arteries of 58 patients with primary systemic amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Evidence of Impaired Left Ventricular Systolic Function by Doppler Myocardial Imaging in Patients With Systemic Amyloidosis and No Evidence of Cardiac Involvement by Standard Two-Dimensional and Doppler Echocardiography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Doppler Myocardial Imaging Compared to Standard Two-Dimensional and Doppler Echocardiography for Assessment of Diastolic Function in Patients With Systemic Amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Cardiac amyloidosis without increased left ventricular wall thickness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Noninvasive diagnosis of cardiac amyloidosis by MRI and echochardiography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Comparison of magnetic resonance imaging versus Doppler echocardiography for the evaluation of left ventricular diastolic function in patients with cardiac amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Intracardiac thrombosis and embolism in patients with cardiac amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Histologic remission of cardiac amyloidosis: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Combined heart and liver transplantation: a single-center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.165

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

31 March 2020

1 reference

12 December 2020

"Congo" red: out of Africa?

1 reference

12 December 2020

Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn's disease: case report and review of the literature

1 reference

12 December 2020

Intra-portal chemoprevention and therapy of liver metastases

1 reference

12 December 2020

Risks of beta-blockers and calcium inhibitors in amyloid cardiopathy

1 reference

12 December 2020

Ten years' experience of an amyloid clinic--a clinicopathological survey

1 reference

12 December 2020

Diagnosis of systemic amyloidosis and amyloidosis mediated cardiomyopathy by VATS pleural biopsy for chronic pleural effusion

1 reference

12 December 2020

Cardiac amyloidosis and the use of diuretic and ACE inhibitor therapy in severe heart failure

1 reference

12 December 2020

Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.

1 reference

12 December 2020

10.1038/NRCARDIO.2014.165

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25311231